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ABSTRACT Despite the administration of multiple drugs that are highly effective in
vitro, tuberculosis (TB) treatment requires prolonged drug administration and is con-
founded by the emergence of drug-resistant strains. To understand the mechanisms
that limit antibiotic efﬁcacy, we performed a comprehensive genetic study to iden-
tify Mycobacterium tuberculosis genes that alter the rate of bacterial clearance in
drug-treated mice. Several functionally distinct bacterial genes were found to alter
bacterial clearance, and prominent among these was the glpK gene that encodes
the glycerol-3-kinase enzyme that is necessary for glycerol catabolism. Growth on
glycerol generally increased the sensitivity of M. tuberculosis to antibiotics in vitro,
and glpK-deﬁcient bacteria persisted during antibiotic treatment in vivo, particularly
during exposure to pyrazinamide-containing regimens. Frameshift mutations in a hy-
pervariable homopolymeric region of the glpK gene were found to be a speciﬁc
marker of multidrug resistance in clinical M. tuberculosis isolates, and these loss-of-
function alleles were also enriched in extensively drug-resistant clones. These data
indicate that frequently observed variation in the glpK coding sequence produces a
drug-tolerant phenotype that can reduce antibiotic efﬁcacy and may contribute to
the evolution of resistance.
IMPORTANCE TB control is limited in part by the length of antibiotic treatment
needed to prevent recurrent disease. To probe mechanisms underlying survival un-
der antibiotic pressure, we performed a genetic screen for M. tuberculosis mutants
with altered susceptibility to treatment using the mouse model of TB. We identiﬁed
multiple genes involved in a range of functions which alter sensitivity to antibiotics.
In particular, we found glycerol catabolism mutants were less susceptible to treat-
ment and that common variation in a homopolymeric region in the glpK gene was
associated with drug resistance in clinical isolates. These studies indicate that revers-
ible high-frequency variation in carbon metabolic pathways can produce phenotypi-
cally drug-tolerant clones and have a role in the development of resistance.
KEYWORDS Mycobacterium tuberculosis, antibiotic resistance, genetics
The currently used multidrug chemotherapy regimen for tuberculosis (TB) wasdeveloped in a series of clinical trials in the 1980s (1) and remains the standard of
care for this disease (2). Infections with drug-sensitive strains of Mycobacterium tuber-
culosis are treated with a 6-month regimen that includes four drugs, isoniazid (INH),
rifampin (RIF), pyrazinamide (PZA), and ethambutol (EMB). While this regimen cures
90% of drug-sensitive cases, the long period over which antibiotics must be adminis-
tered represents a major limitation. Not only is a complete regimen difﬁcult to deliver,
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but even in clinical trial settings, incomplete sterilization leads to relapse in a signiﬁcant
fraction of patients (3). The emergence of drug-resistant strains of M. tuberculosis
further confounds therapy and necessitates even longer regimens with less effective
drugs.
The factors that necessitate this extended drug regimen for TB remain difﬁcult to
dissect because the in vitro efﬁcacy of individual drugs does not predict their effect
during infection. For example, PZA is critical for sterilizing an infected host, but it has
very modest activity in vitro, where it may act via different mechanisms (4). Conversely,
both INH and RIF cause relatively rapid cell death in vitro but kill bacteria much more
slowly during infection. As a result, virtually all TB drug regimens kill bacteria at a lower
rate during infection than they do in axenic culture. Two general mechanisms have
been proposed to explain the generally drug-tolerant phenotype that is observed
during infection. Growth in mammalian tissue triggers changes in mycobacterial gene
expression and metabolism that can reduce drug efﬁcacy (5–7). In addition, a number
of distinct stochastically generated subpopulations have been observed, which arise
either via asymmetric cell division (8) or nonheritable regulatory events (9). Some of
these subpopulations are relatively insensitive to antibiotics in vitro and could prolong
the treatment period necessary for sterilization. While none of these mechanisms
involve heritable genetic changes, many other bacteria rely on high-frequency revers-
ible genetic variation to produce subpopulations that are tolerant to environmental
insults (10). This process of phase variation generally relies on speciﬁc DNA sequences,
such as homopolymeric regions, that are subject to frequent mutation. While phase
variation has been observed in several mycobacterial species (11, 12), it has not been
speciﬁcally characterized in M. tuberculosis, and its potential role in determining drug
efﬁcacy is unknown.
To understand the processes that determine drug efﬁcacy during infection, we
employed two complementary approaches. A forward genetic study identiﬁed bacterial
functions that alter drug efﬁcacy in mice. In parallel, whole-genome sequence analysis
of M. tuberculosis clinical isolates identiﬁed genetic variants in candidate genes that are
associated with resistance. Together, these approaches deﬁned a variable homopoly-
meric region in the glpK gene that controls glycerol metabolism and drug efﬁcacy.
Heritable genetic variation at this site produces a drug-tolerant phenotype that reduces
treatment efﬁcacy and is associated with the emergence of resistant clones.
RESULTS
Genetic determinants of drug efﬁcacy in the mouse model. To speciﬁcally deﬁne
bacterial functions that limit efﬁcacy during infection, we used transposon sequencing
(TNseq) to identify mutations that alter bacterial killing. Groups of mice were infected
with a nearly saturated library ofM. tuberculosis transposon mutants via the intravenous
route. After allowing 2 weeks for bacterial growth and the establishment of adaptive
immunity, animals were treated with a regimen based on ﬁrst-line TB chemotherapy, a
mixture of INH, RIF, PZA, and EMB (HRZE). Each drug in this regimen was shown to be
effective individually at the dose given, and the four-drug mixture reduced organ
burden by more than 100-fold after 14 days of treatment (Fig. 1A). To identify muta-
tions with relatively rapid effects on bacterial killing by antibiotics, mutant pools were
recovered from the spleen after 1 week of therapy by plating organ homogenates. This
analysis was performed in the spleen because this organ contained an adequate
bacterial population size to ensure that complexity of the library was maintained
throughout the infection. In vivo-selected libraries were compared to each other using
TNseq, which quantiﬁes the relative abundance of each mutant in a given pool by
sequencing all the transposon-chromosome junctions that are present (13).
Mutant pools were collected from three groups of animals. A pretreatment pool was
collected immediately before drug administration. One week later, pools from
antibiotic-treated or untreated groups were collected. This study design allowed the
relative ﬁtness of each bacterial mutant to be assessed in the presence and absence of
drug therapy. Pairwise analyses of the treated and untreated pools with the pretreat-
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ment library identiﬁed distinct sets of genes that altered bacterial representation under
each condition (see Table S1 in the supplemental material). As many antibiotics act in
a growth rate-dependent manner, we investigated whether bacterial ﬁtness in vivo was
an important determinant of antibiotic efﬁcacy. When the relative abundance of each
FIG 1 Genetic strategy to deﬁne bacterial functions that limit drug efﬁcacy. (A, left) Spleen CFU from BALB/c mice infected with transposon mutant library both
untreated (circles) and after HRZE treatment (squares). Antibiotic treatment was started at 14 dpi (indicated by gray arrow). Plotted means from 3 biological
replicates with standard deviations are shown. (Right) Change in CFU after treatment with the indicated antibiotic for 5 weeks. The change in CFU between
pretreatment and posttreatment samples is presented. Signiﬁcance was calculated using unpaired t test: *, P  0.03; **, P  0.002; ***, P  0.0002; ****, P 
0.0001. (B) Relative abundance of individual mutants, measured by log2 fold change, in untreated mice (x axis) and HRZE-treated mice (y axis). Signiﬁcantly
altered mutants after treatment are indicated in black. (C) Functional classes of mutants with altered susceptibility in vivo. Classiﬁcation from Mycobrowser. (D
to G) Normalized abundance of mutations in pretreatment (black) and after HRZE treatment (red) at individual TA dinucleotide insertion sites in pncA (D),
ppe50-ppe51 (E), glgA-glgC (F), and glpK (G). Shown are the average numbers of unique sequence reads (y axis) plotted versus TA sites (x axis). (H) Log2 fold
change of individual mutants (gray dots) 1 week posttreatment compared to pretreatment. Signiﬁcantly altered mutants are indicated by black circles.
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mutant in untreated animals was compared with their abundance in time-matched
drug-treated mice, we found no global correlation between bacterial ﬁtness in the
presence and absence of antibiotic (Fig. 1B). However, several individual mutations
were observed that reduced ﬁtness under both conditions. Thus, to more formally focus
our study on drug-related phenotypes, we performed a three-way analysis to identify
those mutations that alter ﬁtness preferentially in antibiotic-treated animals. This
analysis deﬁned 61 mutants that increased, and 8 that reduced, the effect of therapy
(Table S2). These mutants corresponded to a variety of functional pathways (Fig. 1C). In
several cases mutation resulted in dramatic alterations in ﬁtness after drug exposure, as
the relative representation of these mutants under the pre- and posttreatment condi-
tions varied by more than 100-fold.
A number of functions found to alter bacterial ﬁtness in drug-treated mice were
already known to impact drug efﬁcacy. For example, mutants lacking PncA, which
converts PZA into its active pyrazinoic acid form (14), were highly overrepresented in
the treated mice, highlighting the singular importance of PZA in the activity of this
regimen (Fig. 1D). In addition, we found that mutations in mmaA1, mmaA2, and cmaA2
sensitized the bacterium to drug treatment. All of these genes encode functions
necessary for mycolate modiﬁcation, and chemical inhibition of these partially redun-
dant activities has been shown to increase cellular permeability to antibiotics (15).
Additional protein families associated with cell wall structure altered drug efﬁcacy.
PE/PPE family members have been implicated in cell envelope integrity (16), and we
found that mutations in the ppe50-ppe51 pair increased killing (Fig. 1E). Conversely, the
loss of enzymes (ppsA, ppsC, and drrA) necessary for the synthesis of the major cell
envelope lipid, phthiocerol dimycocerosate, decreased clearance. Drug access ap-
peared to be similarly limited by multiple classes of efﬂux pumps, as mutations in
members of the ATP-binding cassette (rv1747), major facilitator superfamily (rv3728),
and MmpL (mmpL8 and mmpL10) families were found to increase bacterial clearance
(Table S2).
In addition to these known mechanisms, we identiﬁed a number of novel functions
that altered bacterial killing. Prominent among these were pathways involved in carbon
metabolism. For example, mutation of both assayable steps of the glycogen synthetic
pathway (glgA and glgC) increased antibiotic activity (Fig. 1F). This pathway promotes
carbon storage through carbohydrate anabolism, a general process that has been
previously implicated in drug tolerance (6). In addition, we identiﬁed the glpK gene,
which encodes the sn-glycerol-3 kinase of M. tuberculosis. Twenty-six of the 29 inser-
tional mutants in this gene showed a similar decrease in clearance rate upon drug
treatment (Fig. 1G). When pools isolated before and after treatment were directly
compared, only pncA mutations produced a statistically signiﬁcant reduction that was
greater than those in glpK (Fig. 1H). This relatively dramatic phenotype was explored in
more detail.
Glycerol metabolism increases drug efﬁcacy in vitro and during murine infec-
tion. GlpK is responsible for phosphorylating the 3-position of glycerol, which is
necessary for its catabolism via the lower glycolytic pathway. To determine if glycerol
catabolism per se was capable of enhancing the activity of TB drugs, the effects of INH,
RIF, and moxiﬂoxacin (MOX) were compared in media containing glycerol or other
carbon sources known to be used during infection, fatty acid and cholesterol (17, 18).
These carbon sources supported different growth rates, which can confound endpoint-
based determinations of antibiotic activity, such as standard MIC measurements. As a
result, we quantiﬁed the growth rate (GR) of bacteria over a time course and deter-
mined the concentration of each drug that was necessary to decrease this rate by 50%,
which is expressed as GR50 (19). Using this approach, we found that glycerol catabolism
produced a modest but reproducible decrease in the GR50 for several drugs. Growth in
glycerol signiﬁcantly increased the efﬁcacy of RIF and MOX compared to growth in
valerate and enhanced the efﬁcacy of INH and MOX compared to growth in cholesterol
(Fig. 2A).
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FIG 2 Glycerol metabolism broadly increases drug efﬁcacy in vitro. (A, top left) Growth of H37Rv on cholesterol and treated with moxiﬂoxacin at the indicated
concentrations. Growth was measured by yellow ﬂuorescent protein (YFP) ﬂuorescence. (Top right) GR50 for moxiﬂoxacin (MOX) in medium containing either
glycerol, valerate, or cholesterol. (Bottom) GR50 ratios for INH (circles), RIF (squares), and MOX (triangles) grown on different carbon sources. Shown are
valerate/glycerol (left) and cholesterol/glycerol (right). Signiﬁcance was calculated using one-sample t test with a theoretical mean value of 0: *, P  0.05; **,
P  0.01. (B) Growth kinetics of H37Rv (circles), oglpK (triangles), and complement (squares) strains on glycerol (top) or glucose (bottom). Plotted means from
3 biological replicates with standard deviations are shown. (C) Growth of H37Rv (black bars), ΔglpK (gray bars), and complement glpK (striped bars) strains after
treatment with INH or RIF in media containing glycerol, butyrate, or pyruvate and PZA in media containing glycerol or dextrose at pH 5.8. Growth was assessed
(Continued on next page)
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To further investigate the role of glycerol metabolism in drug efﬁcacy, a glpK
deletion mutant of M. tuberculosis was constructed. The ΔglpK mutant was unable to
grow in media containing glycerol as the sole carbon source (Fig. 2B), indicating that
the deleted gene encodes the sole glycerol-3 kinase activity. The effect of antibiotics on
the growth rates of glpK-sufﬁcient and glpK-deﬁcient strains was then compared in
media containing different carbon sources. When glycerol was present in the medium,
the ΔglpK mutant was signiﬁcantly less sensitive to INH and RIF than the wild type or
the complemented mutant (Fig. 2C). This difference largely disappeared when glycerol
was replaced with either the nonglycolytic substrate, butyrate, or a glycolytic product
that bypasses the triose phosphate pool, pyruvate. The differential effects of these
carbon sources indicated that the assimilation of exogenous glycerol was primarily
responsible for glpK’s inﬂuence on drug sensitivity. PZA sensitivity was assessed at pH
5.8 to maximize the in vitro efﬁcacy of the drug. However, under these conditions, glpK
deletion did not alter PZA sensitivity. As INH, RIF, and MOX have distinct mechanisms
of action, the effect of glycerol catabolism on antibiotic activity in vitro did not appear
to be speciﬁc to a particular drug or target pathway.
The mouse model was then used to explore the role of glpK during infection.
Consistent with both our TNseq data and previous work (20), deletion of the glpK gene
did not affect the growth or persistence of M. tuberculosis in the lungs of mice after
aerosol infection (Fig. 3A). To quantify the effect of glpK deletion on the efﬁcacy of
individual drugs, mice were inoculated via the intravenous route with a mixture of
wild-type and ΔglpK bacteria and treated with antibiotics, as was done for the initial
TNseq screen. Another mutant lacking the ppe51 gene, which TNseq predicted to be
hypersensitive to multidrug treatment (Fig. 1E), was included as an additional control.
Since this study did not require maintaining the complex mutant mixture needed in the
TNseq study, more prolonged treatment regimens could be used. As we observed
previously, all drug regimens reduced the bacterial burden, and PZA or combination
therapy had the greatest effect (Fig. 3B). Surviving bacteria were recovered by plating
at the indicated time points, and the relative abundance of the three M. tuberculosis
strains was determined by quantitative PCR. Both mutants demonstrated the predicted
phenotypes in animals treated with the four-drug combination therapy for 2 weeks, as
the ΔglpK mutant was cleared signiﬁcantly more slowly and the Δppe51 mutant
signiﬁcantly more rapidly than the wild type (Fig. 3C). These phenotypes were even
more pronounced in animals treated with PZA alone. In contrast to the broadly
sensitizing effect of glycerol catabolism in vitro, the ΔglpK mutant behaved similarly to
the wild type in mice treated with RIF, INH, or EMB. The decreased efﬁcacy of PZA
against the ΔglpK mutant was also found in the lungs of mice infected via aerosol. In
this model, treatment with PZA between 21 and 35 days postinfection reduced the
bacterial burden of wild-type and ΔglpK complemented strains by at least 1,000-fold
but had a signiﬁcantly reduced effect on the glpK-deﬁcient mutant (Fig. 3D). Thus, while
glycerol catabolism can nonspeciﬁcally alter antibiotic susceptibility in vitro, glpK
deletion preferentially reduced the effect of PZA and a PZA-containing multidrug
regimen in this animal model.
Glycerol catabolic defects are associated with extensive drug resistance in
Korea. As the glpK deletion did not alter bacterial ﬁtness during infection and conferred
a beneﬁt upon drug treatment, we hypothesized that mutations altering glycerol
catabolism are positively selected during the evolution of drug resistance in natural
populations. As a ﬁrst test of this hypothesis, we characterized a panel of Korean M.
tuberculosis isolates that varied in drug sensitivity proﬁles, from fully sensitive strains to
extensively evolved clones that were phenotypically resistant to more than ten differ-
FIG 2 Legend (Continued)
by the growth constant, k, normalized to no-antibiotic controls and plotted as ratios (treated/untreated), where 1 is the growth constant without antibiotic
(indicated by a dotted line). Antibiotic concentrations started at 2 g/ml, 1 g/ml, and 400 g/ml for INH, RIF, and PZA, respectively, and were serially diluted
2-fold for 6 dilutions. Signiﬁcance was calculated using an unpaired t test with Benjamini-Hochberg multiple-testing correction. *, P  0.03; **, P  0.002; ***,
P  0.0002; ****, P  0.0001.
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ent antibiotics (see Table S3 for strain characteristics). To investigate whether glycerol
catabolic defects were selected during the evolution of resistance in these strains, we
subcultured a random subset of drug-sensitive or extensively resistant isolates in media
containing glycerol as the sole carbon source. Drug-sensitive strains grew at a rate
FIG 3 Loss of glycerol kinase increases survival under PZA treatment in vivo. (A) Lung CFU of H37Rv (circles) and oglpK (triangles) strains from
BALB/c mice after aerosol infection with a dose of 500 to 700 CFU/mouse. Shown are plotted means from 4 biological replicates with standard
deviations. (B) Spleen CFU from BALB/c mice after intravenous infection with pooled mutant strains both untreated (black circles) and treated with
the indicated antibiotic. Plotted means from 4 biological replicates with standard deviations are shown. (C) Relative abundance of ΔglpK (top) and
Δppe51 (bottom) strains compared to that of the wild type in vivo after antibiotic treatment. Treatment times were 14 days for PZA and MIX, 28
days for RIF, and 35 days for INH and EMB. Individual points are biological replicates normalized to day 0 ratios. Signiﬁcance was calculated using
unpaired t test with Benjamini-Hochberg multiple testing correction: *, P  0.03; **, P  0.002; ***, P  0.0002; ****, P  0.0001. (D) Lung CFU
of H37Rv, ΔglpK, and complement strains from BALB/c mice after aerosol infection and treatment with PZA. Data represent two competition
infections: 1:1 H37Rv and ΔglpK (black and blue circles, respectively) strains, dose of 700 to 1,000 CFU/mouse, and 1:1 H37Rv and complement
(black and gray squares, respectively) strains, dose of 300 to 500 CFU/mouse. Treatment with PZA was started at 21 dpi and continued to 35 dpi.
Shown are plotted means and standard deviations, and individual points are biological replicates. Limits of quantiﬁcation are indicated by dotted
red lines. Signiﬁcance was calculated using unpaired t test with Benjamini-Hochberg multiple testing correction: *, P  0.03; **, P  0.002; ***,
P  0.0002; ****, P  0.0001; ns, not signiﬁcant.
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similar to that of a standard laboratory strain (H37Rv). However, while the extensively
drug-resistant isolates could grow in butyrate, none of the tested isolates could grow
in the glycerol-containing media (Fig. 4A and Table S3).
The whole-genome sequences (WGS) of these isolates were determined. Based on
WGS, this collection was predominantly comprised of a Korean sublineage of East Asian
strains (21), and the multidrug-resistant (MDR) phenotypes could generally be attrib-
uted to known high-level resistance-conferring mutations (Table S4). Inspection of the
WGS data revealed that the glycerol catabolic defect in 9 of the 11 tested strains could
be attributed to loss-of-function mutations in the glpK gene. These strains all harbored
a one-base expansion of the same homopolymeric sequence (GGGGGGG) in the 5= half
of the glpK open reading frame. The sequence of the glpK homopolymer was veriﬁed
in the entire panel by targeted Sanger sequencing (Fig. 4B). This mutation is predicted
to eliminate GlpK enzymatic activity, as it introduces a premature termination codon
that eliminates the majority of the open reading frame, and the same homopolymer
expansion has been previously observed in M. bovis strains lacking glycerol kinase
activity (22). An additional missense mutation altering amino acid 169 was identiﬁed in
an otherwise glpK wild-type allele, but the functional signiﬁcance of this mutation is
unclear. Two of the phenotypically glycerol-deﬁcient strains carried no obvious muta-
tions in glpK or other glycerol catabolic genes. Thus, while glpK frameshifts appear to
be the most common lesion associated with glycerol catabolic defects in this collection,
other mechanisms contribute in a fraction of isolates.
FIG 4 Glycerol catabolic mutations associated with XDR strains. (A) Growth kinetics of drug-susceptible (DS) and drug-resistant (DR) clinical isolates on glycerol-
or butyrate-containing media. Shown are plotted means from 3 biological replicates with standard deviations. (B) Sanger sequencing of glpK from H37Rv and
clinical isolate KT0149-1. The homopolymer region is in the ﬁrst domain of the protein. One-bp insertion changes downstream amino acid sequence and
introduces a premature stop codon at amino acid 252. (C) Phylogenetic tree of M. tuberculosis isolates from Korea with various drug susceptibility proﬁles: DS
(orange); DR, 1 to 4 antibiotics (blue); DR, 5 to 7 antibiotics (green); and DR 7 antibiotics (red). Mutations in glpK gene are indicated: frameshift mutations,
purple stars; missense mutations, purple circles.
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All ten of the glpK frameshifts identiﬁed in this panel were found in multidrug-
resistant strains, particularly the highly evolved strains that were resistant to more than
eight different drugs (Fig. 4C). Based on the phylogenetic relationship between these
strains, the identiﬁed glpK frameshifts represent at least three independent mutational
events. Alternative tree topologies necessary to accommodate fewer mutational events
were signiﬁcantly less likely (P 104). Thus, in this relatively small collection of strains,
inactivating mutations in glpK were frequent and associated with defective glycerol
utilization and drug resistance.
GlpK frameshift mutations are common in M. tuberculosis isolates and associ-
ated with drug resistance in Peru. Frameshift mutations in homopolymeric DNA
sequences can represent high-frequency and reversible events (10). To assess the
frequency of this mutation in a larger population and to further explore its association
with drug resistance, we analyzed the whole-genome sequences of a larger collection
of isolates from Peru. Of 1,031 sequenced strains, 68 isolates harbored nonsynonymous
variants in the glpK gene. Of these, 45 contained a single-base expansion of the glpK
homopolymer and 2 contained a two-base expansion. These frameshifts were found in
all phylogenetic clades of M. tuberculosis, indicating that this mutation has arisen
through multiple distinct mutational events in different lineages of the pathogen
(Fig. 5A and B). In total, homopolymer expansion accounted for 66% of the nonsyn-
onymous glpK variants, and 4.6% of all isolates harbored frameshift mutations disrupt-
ing the glpK open reading frame.
As we found in the smaller set of Korean strains, glpK frameshifts were signiﬁcantly
associated with drug resistance. No instances of glpK frameshifts were found in the 90
phenotypically drug-sensitive strains. In contrast, 44 of the 739 isolates that met the
WHO criteria for MDR carried these mutations (P 3 105). In this large collection,
we were also able to test the association between glpK genotype and resistance to
individual drugs and found signiﬁcant associations with RIF, INH, and ethionamide
(ETH) (Fig. 4C). The lack of observed association with PZA resistance could have been
due to the unreliability of this phenotypic assay. Indeed, using a genotypic assay we
found a signiﬁcant association between glpK frameshifts and nonsynonymous pncA
variants (P 0.001). Thus, the glpK homopolymer is the site of the majority of variation
in this gene, and expansion of this hypervariable region is associated with the evolution
of drug resistance.
DISCUSSION
Drug tolerance has been proposed to contribute to both relapsing TB disease and
the emergence of drug-resistant clones (23). Most current models to explain tolerance
in mycobacteria are largely restricted either to nonheritable processes, such as changes
in gene expression or functionally asymmetric cell division, or stably heritable muta-
tions (24). Our data provide a new mechanism by which alterations in a hypervariable
region in the glpK gene produces bacteria that persist during antibiotic treatment and
could contribute to the emergence of drug-resistant clones.
Insertions and deletions in a homopolymeric region of an open reading frame is a
common mechanism to produce high-frequency reversible phenotypic variation in
bacteria. These mutations are generally thought to result from slipped-strand mispair-
ing during DNA replication. However, additional DNA repair mechanisms, such as
mismatch repair (25) or base excision repair (26), can alter the frequency and directional
bias of the process. The exclusive bias for 1 and 2 frameshifts in the glpK gene of
clinical isolates argues for a more complex process than simple replicative error, and
the ultimate frequency of mutants may also be inﬂuenced by the speciﬁc ﬁtness effect
of each frameshift. As a result, it is difﬁcult to anticipate the rate of variation that occurs
during infection. Regardless, we identiﬁed1 and2 frameshifts in 6% of the Peruvian
MDR isolates. Since clinical samples are routinely cultured in glycerol-containing media,
which would be expected to select for reversion to the wild-type glpK coding sequence,
it is likely our data underestimate the frequency of glpK mutants. The observed
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FIG 5 GlpK mutations associated with drug resistance in clinical isolates from Peru. (A) Phylogenetic tree
ofM. tuberculosis isolates from Peru. GlpK mutations are indicated (red circles). (B) Representation of GlpK
mutations in different lineages: lineage distribution of 1,031 GWAS samples (outer); distribution of 68
glpK mutations (middle); distribution of 45 single-base expansions, T57GT, of the glpK homopolymer
(inner). (C) Association between glpK mutations and drug resistance. Statistical signiﬁcance (*) based on
Bonferroni correction with a type 1 error rate of 0.01. INH, isoniazid; RIF, rifampin; RBU, rifabutin; EMB,
ethambutol; PZA, pyrazinamide; STR, streptomycin; LIN, linezolid; MOX, moxiﬂoxacin; AMK, amikacin;
KAN, kanamycin; CAP, capreomycin; ETH, ethionamide.
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prevalence of this mutation is clearly high enough to produce a signiﬁcant population
of glpK-deﬁcient clones that alter drug efﬁcacy.
Our studies in the mouse model demonstrate that glpK-deﬁcient bacteria are drug
tolerant during infection. The mechanism(s) that underlies the drug tolerance of
glpK-deﬁcient bacteria is likely to be complex. Common fates for glycerol-3-phosphate
are catabolism via the lower glycolytic pathway, incorporation into anabolic pathways,
and spontaneous degradation to methylglyoxal. As a result, glycerol assimilation can
alter growth rate, metabolism, and cellular structure. While not yet conclusive, our in
vitro studies argue against some of these mechanisms. Both the in vitro effects of
glycerol supplementation and the in vivo effects of glpK expression were independent
of growth rate (Fig. 1 and 2), and the differential effect of glpK in glycerol versus
pyruvate growth media indicates that glycolytic ﬂux per se is not the major determinant
of drug efﬁcacy. Thus, we speculate that the abundance of the triose phosphate pool
or some derivative of this pool is primarily responsible for the general enhancement of
antibiotic efﬁcacy that we observed upon glycerol assimilation in vitro.
The nonspeciﬁc effect of glpK on multiple drugs that we observed in vitro is
consistent with previous studies that identiﬁed frameshifts in the glpK homopolymer in
mutants selected for spontaneous resistance to investigational antimycobacterial com-
pounds in vitro (20). Similarly, glpK mutations have also been found in conjunction with
additional mutations in strains selected to be drug tolerant (27) or PZA resistant (28) in
vitro. Despite these relatively general effects on drug activity in vitro, glpK deletion
preferentially reduced the efﬁcacy of PZA-containing regimens in the mouse model
used in this study. This apparent discrepancy could reﬂect differences in drug exposure,
bacterial physiology, or GlpK functions in these two settings. The poor activity of PZA
in vitro, where we observed no effect of glpK on PZA activity, makes it difﬁcult to dissect
these mechanisms in a more controlled system. Regardless, the identiﬁcation of mu-
tations that affect PZA efﬁcacy only during infection highlights the importance of
performing the original TNseq screen in an animal model.
The prevalence of glpK-deﬁcient strains in natural populations and the preferential
survival of these bacteria in drug-treated animals suggested that glpK-deﬁcient clones
contribute to the persistence of M. tuberculosis during therapy and provide precursors
for the emergence of clones with high-level resistance-conferring mutations. It is
unlikely that the effects of glpK variation would be noted in standard phenotypic drug
susceptibility testing (DST). This situation is similar to common variation in the prpR
gene, which speciﬁcally inﬂuences drug tolerance but not DST results (24). These
observations raise the possibility that genotypic tests for common drug tolerance-
inducing variants could predict treatment failure and eventually be used to tailor
therapy. We note that our TNseq study identiﬁed a number of additional loss-of-
function mutations that alter drug efﬁcacy, and the genome contains more than 100
genes with homopolymeric regions that are at least as long as the one found in glpK
(29). Together, these observations suggest that many phenotypically distinct subpopu-
lations arise via similar mechanisms and inﬂuence antibiotic efﬁcacy.
MATERIALS AND METHODS
Transposon sequencing. BALB/cJ (stock no. 000651) mice were purchased from the Jackson
Laboratory (Bar Harbor, ME, USA). Housing and experimentation were in accordance with the guidelines
set forth by the Department of Animal Medicine of University of Massachusetts Medical School and
Institutional Animal Care and Use Committee and adhered to the laws of the United States and
regulations of the Department of Agriculture. Eight- to 12-week-old female animals were infected with
106 CFU of a himar1 transposon library (30) via the intravenous route. Groups of mice were treated with
antibiotics starting at 14 days postinfection. Antibiotics were administered via drinking water at the
following concentrations: 0.1 g/liter isoniazid (Sigma), 0.6 g/liter ethambutol (Sigma), 0.1 g/liter rifampin
(Sigma), and 15 g/liter pyrazinamide (Sigma). At the indicated time points, mice were sacriﬁced, spleens
and lungs were isolated and homogenized, and CFU numbers were determined by plating dilutions on
7H10 agar with 10 g/ml kanamycin. For library recovery, approximately one million CFU per mouse
were plated on 7H10 agar with kanamycin (10 g/ml). Genomic DNA was extracted (13), and the relative
abundance of each mutant was estimated as described previously (13). Statistical analysis of log2 fold
change (log2FC) in counts between conditions (two-way analysis) was performed by resampling (31). The
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three-way analysis measures the difference in log2FC (Δlog2FC) measured under two selective conditions
relative to a common starting condition: Δlog2FC  log2FC(condition 1)  log2FC(condition 2).
In the present case, condition 1 was 14 days postinfection plus 7 days of antibiotic treatment,
condition 2 was 21 days postinfection, and the starting condition was 14 days postinfection (the start of
drug treatment). Statistical signiﬁcance was assessed by resampling. For each gene, the sampling
distribution of Δlog2FC was obtained by resampling with replacement of the insertion counts at each TA
within the gene (after normalization across all libraries). Counts for replicates were pooled prior to
resampling. For each of 10,000 resamples, Δlog2FC was calculated. The P value was taken as the fraction
of the cumulative frequency distribution of Δlog2FC falling outside Δlog2FC 0, on the negative side for
values measured as Δlog2FC  0, or on the positive side for values measured as Δlog2FC  0 (equivalent
to a 1-tailed test). The resulting P values were adjusted for multiple testing by Benjamini-Hochberg false
discovery rate.
M. tuberculosis gene deletion and glpK mutant characterization. M. tuberculosis H37Rv was
maintained in Middlebrook 7H9 medium containing oleic acid-albumin-dextrose-catalase (OADC), 0.2%
glycerol, and 0.05% Tween 80 and grown with shaking (200 rpm) at 37°C. Hygromycin (50 g/ml) or
kanamycin (20 g/ml) was added when necessary. All work with M. tuberculosis adhered to the CDC-NIH
Guide for Biosafety in Microbiological and Biomedical Laboratories (32). glpK and ppe51 were deleted by
allelic exchange as described previously (33), and this work adhered to NIH guidelines for research
involving recombinant DNA molecules. Nucleotides 4138237 to 4139720 (glpK) or 3501829 to 3502901
(ppe51) were replaced by the vector pKM464, including qTag-22 or qTag-26 (34) for glpK and ppe51,
respectively. The ΔglpK strain was cultured in glycerol-free 7H9. Glycerol-dependent growth was assessed
in minimal medium containing asparagine (0.5 g/liter), KH2PO4 (1 g/liter), Na2HPO4 (2.5 g/liter), ferric
ammonium citrate (50 mg/liter), MgSO4·7 H2O (0.5 g/liter), CaCl2 (0.5mg/liter), ZnSO4 (0.1mg/liter), 0.1%
tyloxapol, and either 0.1% glycerol or 0.1% dextrose. For in vitro antibiotic susceptibility testing, isoniazid
and rifampin were used at 2 and 1 g/ml, respectively, and serially diluted 2-fold. Bacteria were
inoculated to a starting optical density at 600 nm (OD600) of 0.05 in 96-well plates with 7H9 medium
containing OADC, 0.05% Tween 80, and 0.2% glycerol, butyrate, or pyruvate. Pyrazinamide was used at
400 g/ml and serially diluted 2-fold. Bacteria were inoculated to a starting OD600 of 0.01 in inkwells
containing 7H9 medium supplemented with OADC, 0.2% glycerol, and 0.05% tyloxapol at pH 5.8 and
grown with shaking. Growth was monitored by OD600. Conditions were assessed in triplicate. Antibiotic
efﬁcacy was determined by comparing growth rate under increasing drug concentrations. OD600 was
plotted and the rate constant (k) value was determined for all conditions using an exponential growth
model. Rate constants posttreatment were normalized to levels for no-antibiotic controls.
ΔglpK mutant ﬁtness in vivo was determined by inoculating mice with a 1:1 mixture of ΔglpK
(hygromycin resistant) and H37Rv (harboring pJEB402 chromosomally integrated plasmid encoding
kanamycin resistance) strains via the aerosol route. At the indicated time points, mice were sacriﬁced and
CFU numbers in spleen and lung homogenate were determined by plating on 7H10 agar. Fitness in the
presence of antibiotic was assessed by a similar competitive assay. Mice were infected with a pool of
strains at equal ratios via the intravenous route (106 total CFU/mouse). Groups of mice were treated with
antibiotics starting at 14 days postinfection, as described for the TNseq study. At the indicated time
points, approximately 10,000 CFU from the spleen homogenate of each mouse were plated on 7H10
agar. Genomic DNA was extracted for quantitative real-time PCR analysis (34). Brieﬂy, the abundance of
the constant and variable regions of the q-Tag present in each mutant was determined by TaqMan PCR
assay, as described previously (34), and used to calculate a variable/constant region ratio for each strain.
The abundance of each mutant strain was then plotted relative to that of wild-type H37Rv (mutant/wild
type). Values were normalized to initial day 0 ratios.
GR50 determination. Bacteria were grown in minimal medium with 0.1% glycerol, 0.1% valeric acid,
or 0.1% cholesterol on 96-well plates. Isoniazid, rifampin, and moxiﬂoxacin were used at 1, 0.062, and
1 g/ml, respectively, and serially diluted 2-fold. A no-antibiotic control was included in each experiment.
Bacteria were inoculated to a starting OD600 of 0.05, and growth was monitored by OD600 and
ﬂuorescence. Conditions were prepared in triplicates. Antibiotic efﬁcacy was determined by growth rate
inhibition. The exponential growth constant (k) value was determined for all conditions. The k value of
each antibiotic concentration was normalized to the k value of the no-drug control. The GR50 value was
determined as the concentration of antibiotic that resulted in a 50% decrease in growth rate, as
previously described (19).
Phenotypic and genotypic analysis of Korean strains. Strains were collected from the National
Culture Collection for Pathogens, which is maintained by the Korea Centers for Disease Control and
Prevention. Phenotypic DST testing for each strain was conducted by an absolute concentration method
using Löwenstein-Jensen agar with critical concentrations of TB drugs (in g/ml): isoniazid (0.2), rifampin
(40), ethambutol (2), streptomycin (10), kanamycin (40), prothionamide (40), cycloserine (30), para-
aminosalicylic acid (1), oﬂoxacin (2), pyrazinamide (50; pH 4.65), capreomycin (40), moxiﬂoxacin (2),
amikacin (40), levoﬂoxacin (2), p-nitrobenzoic acid (500), and rifabutin (40). Strains were classiﬁed as
resistant if drug-containing media produced more than 1% of the CFU observed in control cultures. To
test growth on glycerol, M. tuberculosis was grown in Middlebrook 7H9 broth with 0.5% glycerol, 0.05%
tyloxapol, catalase, and fatty acid-free bovine serum albumin (Sigma). Inocula were cultivated in
7H9-OADC-Tween 80 to an OD of 0.1 to 0.2, washed with phosphate-buffered saline plus tyloxapol
(0.05%), and diluted to 106 CFU/ml.
Genomic DNA was sequenced either by Ion Torrent (yielding an average read length of 170 bases)
or Illumina (300-base paired-end reads) platforms. In both cases, reads were aligned using bwa mem
(version 0.7.12) againstMycobacterium tuberculosis H37Rv reference GenBank accession no. NC_018143.2.
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Variants were called using GATK 3.3-0 (35, 36) by following the developer’s best practices: (i) picard 1.96
MarkDuplicates, (ii) GATK Realigner Target Creator, (iii) GATK IndelRealigner, (iv) GATK BaseRecalibrator,
(v) GATK UniﬁedGenotyper, and (vi) GATK GenotypeGVCFs. Base recalibration was performed iteratively
using the initial Ion variant calls, obtained without recalibration, to obtain a set of polymorphic sites for
use in step 4. Final ﬁltering was performed separately for single-nucleotide polymorphism (SNP) and
insertion/deletion (indel) calls: for SNPs, FS of 60.0, MQ of 40.0, MQRankSum of 12.5, and
ReadPosRankSum of 8.0; for indels, FS of 200.0 and ReadPosRankSum of 20.0. Call-passing
ﬁlters were combined and a ﬁnal ﬁlter QD of 20.0 was applied. Only calls passing all ﬁlters were
combined into the ﬁnal vcf ﬁle (a total of 7,418 variants). For phylogenetic analysis, only variant SNPs
were used. The ﬁnal alignment (which included the corresponding NC_181843.2 reference bases)
consisted of 51 taxa  7,247 positions. A maximum likelihood phylogeny was obtained using PHYML
version 20120412 (37) with the generalized time-reversible model. Trees were visualized with iTOL (38).
Alternative tree topologies were generated using PHYLIP retree (39), and SH tests were performed using
PAML baseml, version 4.8 (40).
Phenotypic and genotypic analysis of Peruvian strains. Drug-resistant phenotypes were deter-
mined by measuring MICs to 12 antituberculosis drugs. For strains found to be sensitive at the critical
concentration recommended by the WHO for each drug (41), we tested two MIC levels below the critical
concentration, and for those resistant at the critical concentration, we tested six levels above it. The
testing concentrations deviated from the traditional doubling in order to better detect intermediate-level
MICs that are theoretically achievable levels in patient sera.
Strains were sequenced on the Illumina platform to produce 100 to 150 paired-end reads and
coverage of at least 50-fold. The paired-end raw sequence data were mapped to the H37Rv reference
genome using the BWA mem algorithm. We used SAMtools (default settings) (42) and pilon (43) to
identify single-nucleotide variants and insertions and deletions up to approximately 100 bp using a
coverage-based approach. We assigned a variant call as missing if the valid depth of coverage at a
speciﬁc site was less than 10 reads, if the mean read-mapping quality at the site did not reach 7, or if
none of the alternative alleles accounted for at least 90% of the valid coverage. The genotype of glpK was
determined by a binary burden score that represented the presence of any nonsynonymous single-
nucleotide variant, insertion, or deletion observed in that gene. M. tuberculosis genetic lineages were
determined using a previously published SNP barcode (44). A neighbor-joining tree was derived using
https://cran.r-project.org/web/packages/ape/index.html.
A linear mixed model was used to examine the associations between glpK genotype and the
rank-transformed MICs phenotypes of 12 drugs and pncA genotype. We adjusted for the population
structure using a genetic relatedness matrix (GRM), calculated from a pairwise distance matrix using
synonymous single-nucleotide variants of the complete genome using the software GEMMA. The type I
error rate was set at 0.01 after a Bonferroni correction accounting for the multiple comparisons. The
linear mixed model was also performed using GEMMA (45).
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